PRINCETON - PDS Biotechnology Corporation (NASDAQ:PDSB) has confirmed plans to commence its VERSATILE-003 Phase 3 clinical trial for a promising cancer immunotherapy within the first quarter of 2025.
Discover the impressive growth and innovation of PDS Health in 2024, including opening 63 new practices and providing over $26 million in donated services.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback